Economic TimesLean R·
MOFSL stays bullish on Sun Pharma; sees 16% upside on innovation pipeline
ET Intelligence Group: Sun Pharma's June quarter performance was broadly in line with analysts' expectations.Expanding specialty and innovative medicines portfolio, semaglutide launches across India and international markets, and the proposed Organon acquisition are major growth drivers in the medium term for the country's largest pharma company by revenue and market cap. Despite pressure in the US generics segment, it has maintained the FY27 guidance of high single-digit revenue growth on acco…
Read at Economic Times →
